Targeting PFKFB3 to restore glucose metabolism in acute pancreatitis via nanovesicle delivery
Our findings identify PFKFB3 as a critical therapeutic target for treating glucose metabolism disorders in acute pancreatitis. Nanovesicle-based PFKFB3 inhibition may serve as an innovative approach to address metabolic complications associated with AP, offering a new direction for therapeutic interventions in inflammatory diseases.
Authors
- Heng Zhu
- Hai Jiang (ORCID: https://orcid.org/0000-0002-4562-2992)
- Zhipeng Xu (ORCID: https://orcid.org/0000-0002-2048-3789)
- Junjie Tao
- Hao Zhang (ORCID: https://orcid.org/0000-0002-9938-8433)
- Jia Liu (ORCID: https://orcid.org/0000-0003-0383-0934)
- Lei Li (ORCID: https://orcid.org/0000-0002-4758-3130)
- Song Qi (ORCID: https://orcid.org/0009-0006-7896-1567)
- Qiang Wang (ORCID: https://orcid.org/0000-0001-9409-0251)
- Qiliang Li (ORCID: https://orcid.org/0000-0003-0387-9551)
Institutions
- First Affiliated Hospital of Bengbu Medical College (CN)
Publication Details
- Journal
- Molecular Medicine
- Published
- 2025-07-05
- DOI
- https://doi.org/10.1186/s10020-025-01261-y
- Primary Topic
- Pancreatitis Pathology and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00